secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001558370-22-008096
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Q1 net loss $13.0M; STRIDE enrollment 50% done; LC-FAOD data in July 2022
-------------------------------------------------------------------------------

- Net loss of $13.0M ($0.53/share) vs $7.2M loss ($3.48/share) in Q1 2021.
- Cash, equivalents and short-term investments of $138.7M as of March 31, 2022.
- R&D expenses rose to $9.3M from $5.5M, driven by STRIDE and FORWARD studies.
- Enrolled 100th patient in STRIDE Phase 2b PMM trial; target enrollment 200.
- Phase 1b and FORWARD natural history study results in LC-FAOD expected July 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000155837022008096/0001558370-22-008096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000155837022008096/rphm-20220510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-008096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer